CA2905531C - Antibody purification and purity monitoring - Google Patents

Antibody purification and purity monitoring Download PDF

Info

Publication number
CA2905531C
CA2905531C CA2905531A CA2905531A CA2905531C CA 2905531 C CA2905531 C CA 2905531C CA 2905531 A CA2905531 A CA 2905531A CA 2905531 A CA2905531 A CA 2905531A CA 2905531 C CA2905531 C CA 2905531C
Authority
CA
Canada
Prior art keywords
recombinant polypeptide
ymc
desired recombinant
antibody
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2905531A
Other languages
English (en)
French (fr)
Other versions
CA2905531A1 (en
Inventor
John A. Latham
Leon F. Garcia-Martinez
Daniel S. Allison
Steven D. Davin
Hoa Binh Do
Geoffrey F. Lee
Ethan W. Ojala
Mark Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CA2905531A1 publication Critical patent/CA2905531A1/en
Application granted granted Critical
Publication of CA2905531C publication Critical patent/CA2905531C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2905531A 2013-03-15 2014-03-17 Antibody purification and purity monitoring Active CA2905531C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792935P 2013-03-15 2013-03-15
US61/792,935 2013-03-15
PCT/US2014/030558 WO2014145744A1 (en) 2013-03-15 2014-03-17 Antibody purification and purity monitoring

Publications (2)

Publication Number Publication Date
CA2905531A1 CA2905531A1 (en) 2014-09-18
CA2905531C true CA2905531C (en) 2023-01-03

Family

ID=51538079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2905531A Active CA2905531C (en) 2013-03-15 2014-03-17 Antibody purification and purity monitoring

Country Status (8)

Country Link
US (3) US9518082B2 (enExample)
EP (2) EP3754012A1 (enExample)
JP (1) JP6472786B2 (enExample)
AR (1) AR095615A1 (enExample)
CA (1) CA2905531C (enExample)
ES (1) ES2834113T3 (enExample)
TW (2) TWI670279B (enExample)
WO (1) WO2014145744A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014145744A1 (en) * 2013-03-15 2014-09-18 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
CN107148283A (zh) * 2014-10-31 2017-09-08 豪夫迈·罗氏有限公司 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
WO2017040992A1 (en) 2015-09-04 2017-03-09 Mo Bio Laboratories, Inc. Methods for co-isolation of nucelic acids and proteins
AU2017229635A1 (en) * 2016-03-07 2018-09-20 Hitachi Chemical Advanced Therapeutics Solutions, LLC A closed system for labelling and selecting live cells
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
CN106371765B (zh) * 2016-08-29 2020-09-18 成都科鸿达科技有限公司 一种高效大规模系统的ltl模型检测去内存抖动的方法
CN106293544B (zh) * 2016-08-29 2020-06-30 成都科鸿达科技有限公司 一种高效大规模系统的ltl模型检测方法
KR102759512B1 (ko) 2016-10-25 2025-02-03 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
JP6829357B2 (ja) * 2017-03-17 2021-02-10 住友ベークライト株式会社 抗体の糖鎖検出法
CN107033236B (zh) * 2017-05-05 2021-03-23 浙江大学 一种从酵母发酵液中分离人血白蛋白的混合模式层析方法
CN107254502A (zh) * 2017-07-26 2017-10-17 兰州名德农牧科技有限公司 一种动物蛋白酶制备羊胎盘肽的方法
MA49962A (fr) 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
KR102825164B1 (ko) * 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
SI3781943T1 (sl) * 2018-04-20 2022-07-29 Janssen Biotech, Inc. Kvalifikacija kromatografske kolone v proizvodnih postopkih za proizvodnjo sestavkov protitelesa proti IL12/IL23
CN112313344A (zh) 2018-04-24 2021-02-02 凯杰科技有限公司 从复杂样品中分离核酸并去除抑制剂
GB201806752D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method in bioprocess system
TWI919355B (zh) 2018-07-02 2026-03-21 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020160161A1 (en) 2019-01-30 2020-08-06 Regeneron Pharmaceuticals, Inc. Method of characterization of visible and/or sub-visible particles in biologics
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
KR20220069053A (ko) * 2019-09-23 2022-05-26 젠자임 코포레이션 제품 품질 특성 측정
CN111239408B (zh) * 2020-01-19 2023-02-10 深圳格道糖生物技术有限公司 特定凝集素组合在构建基于唾液糖蛋白糖链鉴别肝纤维化的测试工具方面的应用
WO2021150996A1 (en) * 2020-01-24 2021-07-29 Amgen Inc. Methods for harvesting biomolecules
JP2020099909A (ja) * 2020-03-17 2020-07-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 処理方法、生産方法およびハイドロキシアパタイト充填剤
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
CN111579777B (zh) * 2020-05-29 2024-02-02 江苏省苏微微生物研究有限公司 一种以大粒径凝胶为载体的亲和介质及其应用
WO2022109171A1 (en) * 2020-11-18 2022-05-27 Modernatx, Inc. Ribonucleic acid purification
GB202105559D0 (en) * 2021-04-19 2021-06-02 Cytiva Bioprocess R & D Ab Method of clarifying a crude protein solution
AU2022271741A1 (en) * 2021-05-10 2023-11-23 Chiome Bioscience Inc. Purification method of antibody composition
CN113416243B (zh) * 2021-08-23 2021-12-10 上海盛迪医药有限公司 一种纯化抗体的方法
CN114279968B (zh) * 2021-12-28 2024-09-20 中国科学院长春应用化学研究所 一种电化学-双偏振干涉光电检测池
CN116675728A (zh) * 2022-01-05 2023-09-01 上海迈晋生物医药科技有限公司 一种纯化蛋白的方法
CN116159340B (zh) * 2022-12-16 2026-06-12 浙江大学 一种用于体积排阻色谱法的缓冲液
WO2025155751A1 (en) * 2024-01-17 2025-07-24 Nutcracker Therapeutics, Inc. Improved method for isolating and characterizing proteins
CN118006716B (zh) * 2024-03-15 2024-09-10 通化安睿特生物制药股份有限公司 制备高表达且低o-糖基化水平的重组人白蛋白的方法
CN119000228B (zh) * 2024-08-26 2025-02-28 西南大学 蛋白质组学样品前处理清洗装置
WO2026120069A1 (en) 2024-12-05 2026-06-11 H. Lundbeck A/S Humanized anti-pacap antibody and uses thereof
CN119832975A (zh) * 2024-12-24 2025-04-15 上海药明生物技术有限公司 一种蛋白质共处方制剂的稳定性预测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6730499B1 (en) 1998-07-03 2004-05-04 Research Corporation Technologies, Inc. Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US20030091976A1 (en) * 2001-11-14 2003-05-15 Ciphergen Biosystems, Inc. Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
WO2004090549A1 (en) * 2003-04-11 2004-10-21 Novozymes A/S Method of screening for secreted glycosylated polypeptides
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
BRPI0608584B8 (pt) * 2005-03-11 2021-05-25 Wyeth Corp métodos de recuperar um produto purificado
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
ES2474940T3 (es) * 2006-12-28 2014-07-10 Janssen Biotech, Inc. Métodos y vectores que generan inmunoglobulinas sialiladas
JP5967861B2 (ja) * 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US20110117601A1 (en) * 2007-08-31 2011-05-19 Markus Haberger Glycosylation Profile Analysis
WO2011049798A1 (en) * 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
SG10201503899SA (en) * 2010-05-18 2015-06-29 Abbvie Inc Apparatus And Process Of Purification Of Proteins
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
CN103827134A (zh) * 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
US10150968B2 (en) 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
SG2014011878A (en) 2011-08-19 2014-04-28 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as a antibodies in transformed microbes such as pichia pastoris
US20140288278A1 (en) * 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2014145744A1 (en) * 2013-03-15 2014-09-18 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring

Also Published As

Publication number Publication date
US10533045B2 (en) 2020-01-14
EP2970865A1 (en) 2016-01-20
JP6472786B2 (ja) 2019-02-20
US12590142B2 (en) 2026-03-31
US9518082B2 (en) 2016-12-13
US20200223913A1 (en) 2020-07-16
ES2834113T3 (es) 2021-06-16
EP3754012A1 (en) 2020-12-23
AR095615A1 (es) 2015-10-28
EP2970865B1 (en) 2020-09-02
CA2905531A1 (en) 2014-09-18
US20140288272A1 (en) 2014-09-25
TW201514195A (zh) 2015-04-16
TW201940691A (zh) 2019-10-16
US20170137500A1 (en) 2017-05-18
TWI670279B (zh) 2019-09-01
JP2016512848A (ja) 2016-05-09
EP2970865A4 (en) 2016-11-09
WO2014145744A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US12590142B2 (en) Antibody purification and purity monitoring
US11649273B2 (en) Anti-VEGF protein compositions and methods for producing the same
JP6280499B2 (ja) Ｆｃ融合タンパク質の精製方法
US10400042B2 (en) Method for increasing pyro-glutamic acid formation of a protein
US20180142038A1 (en) Anti-glycoprotein antibodies and uses thereof
HK40042659A (en) Antibody purification and purity monitoring
CN105229498A (zh) 使用离子交换色谱来控制高甘露糖糖型的水平的方法
US20250129117A1 (en) Rapid purification of monoclonal antibody from in-process upstream cell culture material

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190315

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250121

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250121

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260105